PDF(Pubmed)
Abstract：
UNASSIGNED: A high aspartate aminotransferase/platelet ratio index (APRI) predicts mortality in patients with severe infection. This study aims to assess the potential of APRI as a predictor for mortality in patients with HIV-associated Talaromyces marneffei (HTM).
UNASSIGNED: Associations between APRI and CD4 count, white blood cell count, C-reactive protein (CRP) level, procalcitonin (PCT) level, and cytokines were assessed in 119 patients. Univariate and multivariate Cox regression models were used to predict APRI on 24-week mortality.
UNASSIGNED: APRI was positively associated with CRP (r = 0.190, P = .039), PCT (r = 0.220, P = .018), interleukin 6 (r = 0.723, P < .001), interleukin 10 (r = 0.416, P = .006), and tumor necrosis factor α (r = 0.575, P < .001) and negatively associated with CD4 count (r = -0.234, P = .011). In total, 20.2% (24/119) of patients died within the 24-week follow-up. The 24-week survival rate was 88.0% for patients with APRI <5.6% and 61.1% for those with APRI ≥5.6 (log-rank P < .001). After adjustment for sex, age, body mass index, and CD4 count, as well as serum levels of hemoglobin, APRI ≥5.6 (adjusted hazard ratio [95% CI]; 3.0 [1.2-7.1], P = .015), PCT ≥1.7 ng/mL (3.7 [1.5-9.6], P = .006), and non-amphotericin B deoxycholate treatment (2.8 [1.2-6.6], P = .018) were independent risk factors for 24-week mortality.
UNASSIGNED: For patients with HTM, APRI is associated with severity and is an independent risk factor for 24-week mortality.
UNASSIGNED: Associations between APRI and CD4 count, white blood cell count, C-reactive protein (CRP) level, procalcitonin (PCT) level, and cytokines were assessed in 119 patients. Univariate and multivariate Cox regression models were used to predict APRI on 24-week mortality.
UNASSIGNED: APRI was positively associated with CRP (r = 0.190, P = .039), PCT (r = 0.220, P = .018), interleukin 6 (r = 0.723, P < .001), interleukin 10 (r = 0.416, P = .006), and tumor necrosis factor α (r = 0.575, P < .001) and negatively associated with CD4 count (r = -0.234, P = .011). In total, 20.2% (24/119) of patients died within the 24-week follow-up. The 24-week survival rate was 88.0% for patients with APRI <5.6% and 61.1% for those with APRI ≥5.6 (log-rank P < .001). After adjustment for sex, age, body mass index, and CD4 count, as well as serum levels of hemoglobin, APRI ≥5.6 (adjusted hazard ratio [95% CI]; 3.0 [1.2-7.1], P = .015), PCT ≥1.7 ng/mL (3.7 [1.5-9.6], P = .006), and non-amphotericin B deoxycholate treatment (2.8 [1.2-6.6], P = .018) were independent risk factors for 24-week mortality.
UNASSIGNED: For patients with HTM, APRI is associated with severity and is an independent risk factor for 24-week mortality.
摘要：
■高天冬氨酸转氨酶/血小板比值指数（APRI）可预测严重感染患者的死亡率。本研究旨在评估APRI作为HIV相关马尔尼菲塔拉氏菌（HTM）患者死亡率预测因子的潜力。
■APRI和CD4计数之间的关联，白细胞计数,C反应蛋白(CRP)水平,降钙素原(PCT)水平,对119例患者进行了细胞因子评估。单变量和多变量Cox回归模型用于预测24周死亡率的APRI。
■APRI与CRP呈正相关（r=0.190，P=0.039），PCT（r=0.220，P=0.018），白细胞介素6(r=0.723,P<.001),白细胞介素10（r=0.416，P=0.006），肿瘤坏死因子α(r=0.575,P<.001)与CD4细胞计数呈负相关(r=-0.234,P=.011)。总的来说,20.2%(24/119)的患者在24周随访期间死亡。APRI<5.6％的患者24周生存率为88.0％，APRI≥5.6的患者为61.1％（log-rankP<.001）。在性别调整后，年龄,身体质量指数,和CD4计数，以及血红蛋白的血清水平，APRI≥5.6（调整后的危险比[95%CI]；3.0[1.2-7.1]，P=.015)，PCT≥1.7ng/mL（3.7[1.5-9.6]，P=.006)，和非两性霉素B脱氧胆酸治疗（2.8[1.2-6.6]，P=0.018）是24周死亡率的独立危险因素。
■对于HTM患者，APRI与严重程度相关，是24周死亡率的独立危险因素。
■APRI和CD4计数之间的关联，白细胞计数,C反应蛋白(CRP)水平,降钙素原(PCT)水平,对119例患者进行了细胞因子评估。单变量和多变量Cox回归模型用于预测24周死亡率的APRI。
■APRI与CRP呈正相关（r=0.190，P=0.039），PCT（r=0.220，P=0.018），白细胞介素6(r=0.723,P<.001),白细胞介素10（r=0.416，P=0.006），肿瘤坏死因子α(r=0.575,P<.001)与CD4细胞计数呈负相关(r=-0.234,P=.011)。总的来说,20.2%(24/119)的患者在24周随访期间死亡。APRI<5.6％的患者24周生存率为88.0％，APRI≥5.6的患者为61.1％（log-rankP<.001）。在性别调整后，年龄,身体质量指数,和CD4计数，以及血红蛋白的血清水平，APRI≥5.6（调整后的危险比[95%CI]；3.0[1.2-7.1]，P=.015)，PCT≥1.7ng/mL（3.7[1.5-9.6]，P=.006)，和非两性霉素B脱氧胆酸治疗（2.8[1.2-6.6]，P=0.018）是24周死亡率的独立危险因素。
■对于HTM患者，APRI与严重程度相关，是24周死亡率的独立危险因素。
